OOIR: Observatory of International Research

Papers

(The H4-Index of JAMA Neurology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza	462
Burden of Neurological Disorders Across the US From 1990-2017	317
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease	304
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome	297
Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children	297
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum	269
Association of Delirium With Long-term Cognitive Decline	265
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	243
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis	234
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease	204
Global Prevalence and Incidence of Tinnitus	183
Global Prevalence of Young-Onset Dementia	179
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease	175
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	170
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy	170
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease	169
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel	167
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US	166
Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy	163
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex	162
Clinical Presentation, Investigation Findings, and Treatment Outcomes of Spontaneous Intracranial Hypotension Syndrome	160
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	154
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study	150
Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing	148
Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients	145

Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy	140
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab	139
Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study	138
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes	131
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	130
Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging	129
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease	124
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability	124
Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes	123
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	119
Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis	117
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis	116
Autoimmune Encephalitis Misdiagnosis in Adults	114
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis	114
Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets	112
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died	111
Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US	109
Seizure Cycles in Focal Epilepsy	107
Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders	106
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis	104
Thrombectomy for Primary Distal Posterior Cerebral Artery Occlusion Stroke	101
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers	99
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease	99
Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension	99
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis	98
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis	95
Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease	95
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease	94
Association of NO₂ and Other Air Pollution Exposures With the Risk of Parkinson Disease	93
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia	92
Recovery of Consciousness and Functional Outcome in Moderate and Severe Traumatic Brain Injury	92
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	90
Association of Field Position and Career Length With Risk of Neurodegenerative Disease in Male Former Professional Soccer Players	89
Prevalence of High-risk Plaques and Risk of Stroke in Patients With Asymptomatic Carotid Stenosis	88
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	87
Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US	87
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis	86
Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone	86
Trends in Relative Incidence and Prevalence of Dementia Across Non-Hispanic Black and White Individuals in the United States, 2000-2016	85
Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California	85
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease	83
Association of Daily Step Count and Intensity With Incident Dementia in 78 430 Adults Living in the UK	83
Encephalitis Induced by Immune Checkpoint Inhibitors	80
Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients With Acute Stroke	79
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	78
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology	75
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease	75
Comparison of Prehospital Scales for Predicting Large Anterior Vessel Occlusion in the Ambulance Setting	74
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis	74